Sandoz chalks up another settlement in US generic drug price fixing case
NewsletterReceive the most important news of the day by email
Sandoz will pay $275 million to settle further claims under the US generic
drug industry antitrust litigation, ticking another group of...
19 hours ago
from: FirstWord Pharma
- Sandoz settles US antitrust case for $275m Sandoz (SIX:SDZ), a division of Novartis (SIX:NOVN), has reached a $275
million settlement agreement with the end payer plaintiffs in a US...
from: Investing.com
- Sandoz: measures to resolve US antitrust dispute Sandoz today announced a series of steps aimed at resolving the U.S.
generic antitrust class action litigation. Sandoz has reached a...
from: marketscreener.com